The pathobiology of select adolescent young adult lymphomas.

Autor: Steidl C; Centre for Lymphoid Cancer BC Cancer Vancouver British Columbia Canada., Kridel R; Princess Margaret Cancer Centre - University Health Network Toronto Ontario Canada., Binkley M; Department of Radiation Oncology Stanford University Stanford California USA., Morton LM; Radiation Epidemiology Branch Division of Cancer Epidemiology and Genetics National Cancer Institute Rockville Maryland USA., Chadburn A; Department of Pathology and Laboratory Medicine Weill Cornell Medicine New York New York USA.
Jazyk: angličtina
Zdroj: EJHaem [EJHaem] 2023 Sep 29; Vol. 4 (4), pp. 892-901. Date of Electronic Publication: 2023 Sep 29 (Print Publication: 2023).
DOI: 10.1002/jha2.785
Abstrakt: Lymphoid cancers are among the most frequent cancers diagnosed in adolescents and young adults (AYA), ranging from approximately 30%-35% of cancer diagnoses in adolescent patients (age 10-19) to approximately 10% in patients aged 30-39 years. Moreover, the specific distribution of lymphoid cancer types varies by age with substantial shifts in the subtype distributions between pediatric, AYA, adult, and older adult patients. Currently, biology studies specific to AYA lymphomas are rare and therefore insight into age-related pathogenesis is incomplete. This review focuses on the paradigmatic epidemiology and pathogenesis of select lymphomas, occurring in the AYA patient population. With the example of posttransplant lymphoproliferative disorders, nodular lymphocyte-predominant Hodgkin lymphoma, follicular lymphoma (incl. pediatric-type follicular lymphoma), and mediastinal lymphomas (incl. classic Hodgkin lymphoma, primary mediastinal large B cell lymphoma and mediastinal gray zone lymphoma), we here illustrate the current state-of-the-art in lymphoma classification, recent molecular insights including genomics, and translational opportunities. To improve outcome and quality of life, international collaboration in consortia dedicated to AYA lymphoma is needed to overcome challenges related to siloed biospecimens and data collections as well as to develop studies designed specifically for this unique population.
Competing Interests: The authors declare no conflict of interest.
(© 2023 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz: